Zydus Cadila to bolster biologic business with new products

The Ahmedabad-based Zydus Cadila is planning to scale up its biologics business with a slew of launches by next year. The company hopes to have a portfolio of around 15 products in the market in a couple of years.
 
Biopharmaceuticals or biologics as they are also known are basically products that are extracted from or manufactured in biological sources, and are distinct from chemically synthesized pharmaceutical compounds. Biologics could be novel compounds or copy-cats called biosimilars.
 
Zydus Cadila is already working on novel biologics as well as biosimilars. “In India we already have six products in the market, and is one of the larger players in the segment. It plans to launch at least one to three products by next year in the segment,” informed a senior company official.
 
It is pushing three programs in biologics the US, and back in India it has 18 programs, and by next year it should have around nine products in the market. In another couple of years, Zydus would have a portfolio of at least 15 biologics in the Indian market. There are plans to have two would be novel biologics which should be in the market in about three years.